TABLE 1.
Baseline characteristics of hairy cell leukemia (HCL) patients.
| Baseline characteristics (N = 14) | |
|---|---|
| Age at HCL diagnosis, median (range) | 47 (23–67) |
| Sex, n (%) | |
| Female | 4 (28.6) |
| Male | 10 (71.4) |
| COVID‐19 diagnosis and vaccination status | |
|---|---|
| Vaccinated, n (%) | |
| No | 3 (21.4) |
| Yes | 11 (78.6) |
| First vaccination before positive COVID‐19 testing | 5 (35.7) |
| First vaccination after positive COVID‐19 testing | 6 (42.9) |
| Vaccination dose and type, n (%) (n = 11) | |
| One dose: Moderna | 1 (9.1) |
| Two doses (same product): | 5 (45.5) |
| Moderna | 2 |
| Pfizer | 2 |
| Janssen | 1 |
| Three doses: | 5 (45.5) |
| Moderna | 2 |
| Pfizer | 3 (1 previously received Janssen) |
| HCL treatment history | |
|---|---|
| Has HCL been treated, n (%) | |
| No | 3 (21.4) |
| Yes | 11 (78.6) |
| Number of lines of prior treatment (n = 11) | |
| Median (range) | 2 (1–4) |
| On Tx at COVID‐19 dx?, n (%) | |
| No | 9 (81.8) |
| Yes | 2 (18.2) |
| NA | 2 |
| Last IgG level prior to COVID‐19 Dx | |
| Median (range) | 988 (728–1216) |
| NA | 8 |
| Last CD4 count | |
| Median (range) | 349 (259–460) |
| NA | 9 |
| Last CD8 count | |
| Median (range) | 157 (112–380) |
| NA | 9 |
| Management of COVID‐19 | |
|---|---|
| Treatment, n (%) | |
| Monoclonal antibody a | 7 (50) |
| Remdesivir | 1 (7.1) |
| Other b | 2 (28.6) |
Abbreviations: IgG, immunoglobulin G; NA, not available.
a
Monoclonal antibody received: casirivimab, imdevimab (n = 1), sotrovimab (n = 2), and bamlanivimab (n = 2).
b
Other treatments: antibiotics (n = 1) and Paxlovid (n = 1).